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Conclusions: Greater concentrations of CD40L and TNF-B were seen at the site of
stenosis and may promote inflammation in symptomatic SFA disease. A local inflamma-
tory response is particularly notable in newly diagnosed, symptomatic patients not
currently taking aspirin, clopidogrel or a statin.
TCT-158
Impact Of Subclinical Peripheral Arterial Disease Severity On Middle And
Long Term Outcomes In Patients With ST-Elevation-Myocardial Infarction
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Background: The presence of clinical peripheral arterial disease (PAD) is associated
with an increased risk of adverse cardiovascular outcomes among patients with coronary
artery disease (CAD). However, there is little data regarding the impact of the presence
and degree of the subclinical PAD on outcomes in patients with CAD, specially those that
undergoing percutaneous coronary intervention (PCI) for ST-elevation-myocardial infarc-
tion (STEMI). We aimed to assess prospectively the grade of subclinical PAD in the
setting of patients that undergoing primary PCI for prediction of middle and long-term
clinical outcomes.
Methods: A total of 971 consecutive patients without history of clinical PDA that
undergoing primary PCI for STEMI were included in a prospective follow-up. Subclinical
PAD severity was blindly assessed based on a previously described ultrasound arterial
morphology classification (UAMC) defined with an high-resolution ultrasound assess-
ment of wall carotid and femoral artery bifurcations. This classification included four
classes (I: normal, II: wall thickening, III: non-stenosing plaques, IV: stenosing plaques)
corresponding to four scores ranging between 2 and 8 for each artery (total score from 8
to 32 in each patient. The group was divided into four classes according to UAMC and
each patient was assigned a score. We evaluated death, and major cardiovascular and
cerebrovascular events after 40 months’mean follow-up.
Results: At multivariable analysis, mortality in class IV group was more than 16-fold
higher (hazard ratio [HR], 16.50; 95% confidence interval [CI], 7.76 to 35.07; P0.001)
when compared with the class I group and was also increased in the class III group (HR,
4.47; 95% CI, 2.55 to 8.76; P0.001) and class II group (HR, 1.62; 95% CI, 1.30 to 2.18;
P 0.05). Similarly, an increasing effect was seen across UAMC strata for MACCE in the
class IV group (HR, 12.29; 95% CI, 9.16 to 16.50; P0.001), class III group (HR, 11.70;
95% CI, 8.54 to 16.24; P 0.001), and class II group (HR, 1.92; 95% CI, 1.40 to 2.55;
P0.005).
Conclusions: The UAMC may be applied in the STEMI population that undergoing
primary PCI and is able to stratify patients for poor middle and long term clinical
outcomes.
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Background: At physiologic pressures, the elastin fiber network constrains artery
diameter. Fragmenting elastin fibers following successful angioplasty of atherosclerotic
arteries could result in larger artery lumen diameter and area. The purpose of this study
was to investigate the use of PRT-201, a recombinant human type I pancreatic elastase,
as an adjuvant therapy to balloon angioplasty for treatment of peripheral artery disease
(PAD).
Methods: Diseased tibial arteries were harvested from patients undergoing lower limb
amputations for PAD. Ex vivo balloon angioplasty was performed using a balloon chosen
to match the lumen diameter of the artery taken at the intima-plaque interface. Thereafter,
the arteries were cut into 6 x 1.5 mm rings and studied on a wire myograph to obtain
baseline compliance data. Then the external surface of the artery was bathed in PRT-201
2 mg/mL or saline for 60 minutes and myography was repeated. Treated rings were
analyzed for desmosine (elastin) content by RIA and elastin fiber staining by histology.
Desmosine is a protein cross-link unique to elastin.
Results: PRT-201 but not saline caused a shift in the compliance curve of artery rings
from the anterior and posterior tibial arteries (Figure) associated with an increases in
lumen diameter and area across a range of pressures. PRT-201 treatment reduced
desmosine (elastin) content by 60% and reduced elastin fiber staining on histology.
Conclusions: The results suggest that PRT-201 treatment following balloon angioplasty
of atherosclerotic arteries could increase artery lumen diameter and area without requiring
placement of a stent.
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Effects of PRT-201, a Recombinant Human Type I Pancreatic Elastase,
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Background: At physiologic pressures, elastin fibers constrain artery diameter. Remov-
ing elastin fibers from an atherosclerotic artery could result in larger artery lumen diameter
and greater blood flow. The purpose of this study was to investigate the use of PRT-201
as a treatment for peripheral artery disease (PAD).
Methods: Anterior and posterior tibial arteries were obtained within 24 hrs of death from
persons who donated their bodies to science. The arteries were visually atherosclerotic.
3-4 cm long segments of artery were mounted onto the perfusion myograph and bathed
in Krebs solution at 37C gassed with a mix of 95% O2/ 5% CO2. Transmural pressures
were increased from 10 to 80 mmHg while diameter was continuously recorded to create
a compliance curve. Then PRT-201 was applied at a concentration of 3.6 mg/mL for 30
min and the compliance curve was repeated. The artery was analyzed for elastin content
by desmosine radioimmunoassay (RIA). Desmosine is a protein cross-link unique to
elastin.
Results: 6 donors provided 10 tibial arteries. The figure displays the compliance curves
for the tibial arteries pre- and post-PRT-201. Average anterior tibial artery diameter
increased by 0.78  0.21 mm (27  12%) and average posterior tibial artery diameter
increased by 0.58  0.30 mm (21  11%), all p0.001, following PRT-201 treatment.
PRT-201 reduced elastin content measured by desmosine RIA by approximately 50%.
Conclusions: PRT-201 treatment removed elastin from atherosclerotic tibial arteries and
altered artery compliance so as to increase artery diameter.
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Long term effect of transcatheter intra-arterial administration of bone
marrow mononuclear cells in patients with critical limb ischemia
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Background: Therapeutic vasculogenesis in patient with critical limb ischemia (CLI) is
an experimental method with good short term results. Successful vasculogenesis is
achieved by transcatheter intra-arterial administration of autologous bone marrow mono-
nuclear cells (BMMC) directly into the ischemic foot. However, the longterm effects of
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this techniques is not well established. We sought to assess the long-term effects of
intrarterial infusion of BMMC in patients with CLI.
Methods: from September 2004 to December 2007 intrarterial infusion of BMMC was
performed in 28 subjects with CLI (fontain grade 3 and 4, 17 men and 11 women). The
mean age was 60 years. 50% of subject in the study population had ischemic defects in
the Lower limb, 53.5% diabetes mellitus, 42.8% ischemic heart disease, 67.8% arterial
hypertension, 21.4% thrombangitis obliterans and 50% hyperlipoproteinemia.
Results: Major amputation was performed during follow up in 2 subjects 3 months after
BMMC implantation. 11 of the 14 fourteen subject with defect had healed (79%) and the
Fontaine grade improved to grade 2B in 22 subjects (84.6%). In 2 patients (7.6%) resting
pain remained in spite of defects healing but were well controlled with analgesics. In 2
subjects the size of the defect was reduced one year after BMMC treatment but did not
heal. The mean ankle brachial index was improved with treatment (0.54 vs 0.67, p
0.0001) and the mean tpO2 was improved (14.9 vs 37.2 mmHg, p 0.0001). The
overall quality of life assessed using SF-36 questionnaire was also dramatically improved
after one year (p 0.0001).After 5 years of follow up 14 patients had died (50%) due to
multiple cardiovascular comorbidities. 11 individual (39%) were without resting pain and
in the fontain class 2B. 3 patients (10%) were asymptomatic. None of the patient in the
surviving group underwent major amputation or had ischemic defect.
Conclusions: Transcatheter intra-arterial administration of BMMC is a suitable alterna-
tive for treatment of patients with critical limb ischemia. However, the midterm benefits
of this method are limited by long term unfavorable outcome due to high mortality caused
by cardiovascular comorbidities
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Distal Embolization and Protective Devices: Mortality, Operating Room Time,
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Eric Dippel1, Niraj Parikh2, Ryan Egeland3, Katrine Wallace2
1Midwest Cardiovascular Research Foundation, Davenport, IA, 2Covidien,
Mansfield, MA, 3Covidien, Minneapolis, MN
Background: Distal embolization (DE) events are commonly reported in percutaneous
atherectomy procedures. Embolic protection (EP) devices reduce these events. This study
compared inpatient hospital costs and resource utilization in two non-coronary (presumed
lower extremity) atherectomy patient populations: (1) a DE event group, and (2) an EP
group.
Methods: All inpatient discharges for atherectomy of non-coronary vessels (ICD-9-CM
procedure code 39.50) were selected from a comprehensive hospital admissions database
(Premier Perspective CY2005-20 10). DE patients were identified using ICD-9-CM
diagnosis codes (444.XX, 434.0, and 434.1). Patients receiving EP devices were identified
using a billing data keyword search. Discharges in the DE and EP groups were propensity
matched adjusting for age, gender, race and severity scores. Inpatient mortality, length of
stay, operating room (OR) time, and costs were compared between the groups.
Results: After propensity matching DE and EP groups, there were n1,497 matched
pairs. The inpatient mortality rate was significantly higher in DE compared to EP (2.7%
vs. 1.3%, p0.05). Hospital stay averaged 1.4 days longer in the DE patients (p0.05).
Room and board, surgery and pharmacy costs were significantly higher for DE (p0.05).
OR time was 24 minutes longer for DE patients. Total costs were higher but not
significant for the DE group ($24,326 vs. $23,594, p0.38). As a reference, the total rate
of embolic events detected in this inpatient population was 13.5 percent.
Conclusions: The use of embolic protection is strongly associated with lower inpatient
mortality rates, shorter hospital stays, and shorter OR times. Cumulatively, these findings
demonstrate embolic protection devices may significantly reduce consumption of hospital
resources.
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single center DEB-BTK Registry
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Background: Recent registries and randomized trials support the role of percutaneous
revascularization in patients with critical limb ischemia (CLI) and life limiting claudica-
tion (LLC) due also to infragenicular atherosclerotic disease. However, the percutaneous
transluminal angioplasty (PTA) may result in high restenosis rate and target lesion
revascularization.Promising results are coming from ond randomised controlled study an
single center registries using drug eluting balloon (DEB) in this arterial district.
Methods: Between December 2008 and December 2010, 75 (48 males) consecutive
patients underwent percutaneous revascularization of below the knee(BTK) arteries in our
institution due to CLI(58[72.5%]) and LLC(17[27.5%]). Functional status was Rutheford
class 3 in 4 (5%) patients, class 4 in 24(30%) patients, class 5 in 37(50%), and class 6 in
10(15%). All patients(98 lesions) were treated predilating with an undersized standard
balloon and then with Pacltaxel Eluting Balloon In.Pact Amphirion (Medtronic).No
limitation in number of vessels treated, lesion length were considered (mean treated length
8925 mm). A total occlusion was the target lesion in 47% of cases. In 22 cases above
the knee arteries were previously treated.Polpliteal artery was the target lesion in 17 cases,
anterior tibial artery in 28 cases, posterior tibial artery in 23 cases, peroneal artery in 16
cases.
Results: Procedural success, meaning angiographic evidence of restored antegrade flow,
was achieved in 70 (94%) patients. Bail-out stenting for flow limiting dissection or abrupt
target vessel occlusion was needed in 7 patients(10%). Procedural complication:distal
embolization 2(2.5%),access site complication 1(1.5%), intra-hospital mortality
1(1,5%).The rate of angiographic restenosis at twelve months was 24% (n15). Only
symptomatic patients were planned for a reintervention(n9). One-year primary patency
was 76%(n52); secondary patency was 91% (n61).
Conclusions: The outcome of this single center experience suggest that the use of drug
eluting balloon for percutaneous transluminal angioplasty of below the knee arterial
lesions is feasible, safe, and provides favourable one-year clinical results in patients with
CLI.
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Compared to Bare Metal Stents: a meta-analysis
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Background: Drug eluting stents (DES) have become the standard therapy for coronary
interventions, however its benefits on peripheral artery disease are not as clear, particularly
in below-knee peripheral arterial disease.
Methods: All randomized controlled trials of drug eluting stents in below-knee peripheral
artery disease were sought in PubMed, and Cochrane databases during May 2012. Data
was extracted by 3 reviewers and analyzed with RevMan 5.1 software.
Results: Four randomized controlled trials were found. Our analysis demonstrated a clear
benefit in patency manifested by a freedom of target lesion revascularization up to four
times higher with DES (p0.001, Figure1) and an improvement of at least one level on
the Rutherford classification up to two times higher at 6 to 12 months (p0.005, Figure
2). There was a non significant trend favoring DES in reducing major amputations (Figure
3) and death incidence was similar.
Conclusions: Our meta-analysis shows that DES significantly improves patency and
symptoms when compared to BMS for the revascularization of below-knee arterial
disease.
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Evaluation of Long-term Vascular Responses to Fluorocopolymer coated Self-
Expanding low-dose Paclitaxel-eluting Stent in Porcine Ilio-femoral Model
Dongming Hou1, Barbara Huibregtse2, William Stoffregen3, Gordon Kocur1,
Cory Hitzman1, Elizabeth Stejskal1, John Heil1, Keith Dawkins4
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Background: Peripheral interventional therapy to treat occlusive disease for patients
with symptomatic claudication is considered standard clinical practice. The present study
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